Treatment Responder Rates of Oral Atogepant for the Preventive Treatment of Chronic Migraine: Results From the PROGRESS Trial

被引：0

作者：

Lipton, Richard B. ^{[1
]}

Ashina, Messoud ^{[2
]}

Tassorelli, Cristina ^{[3
]}

Martin, Vincent ^{[4
]}

Yu, Sung Y. ^{[5
]}

Nagy, Krisztian ^{[6
]}

Schwefel, Brittany ^{[7
]}

Trugman, Joel ^{[5
]}

机构：

[1] Albert Einstein Coll Med, Bronx, NY USA

[2] Univ Copenhagen, Dept Neurol, Danish Headache Ctr, Rigshospitalet Glostrup, Cophenhagen, Denmark

[3] C Mondino Fdn & Univ Pavia, Headache Sci Ctr, Pavia, Italy

[4] Univ Cincinnati, Cincinnati, OH USA

[5] AbbVie, Madison, NJ USA

[6] AbbVie, Budapest, Hungary

[7] AbbVie, N Chicago, IL USA

来源：

CEPHALALGIA | 2022年 / 42卷 / 1_SUPPL期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

MTIS22-EP-

引用

页码：31 / 32

页数：2

共 50 条

[31] Atogepant provides early improvements in daily functioning and quality of life: results from the PROGRESS chronic migraine trial
Ailani, J.
Gandhi, P.
Dodick, D. W.
Reuter, U.
Schwedt, T. J.
Liu, Y.
Dabruzzo, B.
Stokes, J.
Lipton, R. B.
JOURNAL OF HEADACHE AND PAIN, 2024, 25
[32] Atogepant Provides Early Improvements in Daily Functioning and Quality of Life: Results from the PROGRESS Chronic Migraine Trial
Ailani, J.
Dodick, D.
Reuter, U.
Schwedt, T.
Liu, Y.
Dabruzzo, B.
Stokes, J.
Gandhi, P.
Lipton, R.
HEADACHE, 2023, 63 : 117 - 118
[33] Atogepant demonstrates early functional and quality of life improvements for the preventive treatment of episodic migraine after prior inadequate response to treatment: results from the ELEVATE trial
Holle-Lee, D.
Gandhi, P.
Reuter, U.
Ailani, J.
Lipton, R. B.
Nagy, K.
Liu, Y.
Carr, K.
Stokes, J.
Tassorelli, C.
JOURNAL OF HEADACHE AND PAIN, 2024, 25
[34] Atogepant Significantly Reduces Mean Monthly Migraine Days in the Phase 3 Trial (ADVANCE) for the Preventive Treatment of Migraine
Ailani, Jessica
Lipton, Richard
Goadsby, Peter
Guo, Hua
Miceli, Rosa
Severt, Lawrence
Finnegan, Michelle
Trugman, Joel
NEUROLOGY, 2021, 96 (15)
[35] Atogepant significantly reduces mean monthly migraine days in the phase 3 trial (ADVANCE) for the preventive treatment of migraine
Ailani, J.
Lipton, R. B.
Goadsby, P. J.
Guo, H.
Miceli, R.
Severt, L.
Finnegan, M.
Trugman, J. M.
HEADACHE, 2021, 61 : 99 - 100
[36] Sustained response to atogepant in individuals with episodic migraine and prior inadequate response to preventive treatment and in individuals with chronic migraine: post-hoc analyses from ELEVATE and PROGRESS
Lipton, R. B.
Chalermpalanupap, N.
Tatsuoka, Y.
Nagy, K.
Liu, Y.
Carr, K.
McAllister, P.
Nahas, S. J.
Trugman, J. M.
Sacco, S.
JOURNAL OF HEADACHE AND PAIN, 2024, 25
[37] Kinetic Oscillation Stimulation for the preventive treatment of chronic migraine: results from a randomized-controlled trial
Hoffmann, J.
Kaube, H.
Rimmele, F.
Juergens, T.
Nissilae, M.
Gaul, C.
Kallela, M.
Keski-Saentti, P.
Sumelahti, M.
Straube, A.
Lewis, D.
May, A.
HEADACHE, 2023, 63 : 143 - 144
[38] Weight loss with atogepant during the preventive treatment of migraine: A pooled analysis
Peterlin, B. Lee
Bond, Dale S.
Ailani, Jessica
Dodick, David W.
Liu, Yingyi
Ferreira, Rosa De Abreu
Smith, Jonathan H.
Dabruzzo, Brett
Goadsby, Peter J.
Trugman, Joel M.
CEPHALALGIA, 2024, 44 (12)
[39] Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial (vol 402, pg 775, 2023)
Pozo-Rosich, P.
Ailani, J.
Ashina, M.
LANCET, 2023, 402 (10410): : 1328 - 1328
[40] Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial (vol 402, pg 775, 2023)
Pozo-Rosich, P.
Ailani, J.
Ashina, M.
LANCET, 2023, 402 (10404): : 774 - 774

← 1 2 3 4 5 →